Stay updated with breaking news from Janani rangaswami. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Empagliflozin s efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status. ....
"This is exactly what we need: a well-done trial with a control group to show that it actually works," said one expert, cautioning that it provides only proof of concept. ....